Oral nano‐curcumin formulation efficacy in management of mild to moderate hospitalized <scp>coronavirus disease</scp>‐19 patients: An open label nonrandomized clinical trial
Niloofar Saber‐Moghaddam, Soofia Salari, Sepideh Hejazi, Mahnaz Amini, Zhila Taherzadeh, Saeed Eslami, Seyed Mahdi Rezayat, Mahmoud Reza Jaafari, Sepideh Elyasi
Abstract
Curcumin is proposed as a potential treatment option for coronavirus disease‐19 (COVID‐19) by inhibiting the virus entrance, encapsulation and replication, and modulating various cellular signaling pathways. In this open‐label nonrandomized clinical trial, efficacy of nano‐curcumin oral formulation has been evaluated in hospitalized patients with mild–moderate COVID‐19. Forty‐one patients who fulfilled the inclusion criteria were allocated to nano‐curcumin ( n = 21) group (Sinacurcumin soft gel, contains 40 mg curcuminoids as nanomicelles, two capsules twice a day) or control ( n = 20) group, for 2 weeks. Patients' symptoms and laboratory data were assessed at baseline and during follow‐up period. Most of symptoms including fever and chills, tachypnea, myalgia, and cough resolved significantly faster in curcumin group. Moreover, SaO 2 was significantly higher in treatment group after 2, 4, 7, and 14 days of follow‐up and lymphocyte count after 7 and 14 days. Duration of supplemental O 2 use and hospitalization was also meaningfully shorter in treatment group. It is also noteworthy to mention that no patient in treatment group experienced deterioration of infection during follow‐up period, but it occurred in 40% of control group. Oral curcumin nano‐formulation can significantly improve recovery time in hospitalized COVID‐19 patients. Further randomized placebo controlled trials with larger sample size are recommended.